View
1
Download
0
Category
Preview:
Citation preview
March 2019
2018 Annual Results Presentation
1Copyright© 2019 Innovent Biologics
This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future
results of operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our business strategy and plans, the clinical development of our product candidates
and our objectives for future operations, are forward-looking statements. The words “anticipate,” believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “will” and similar
expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future
events and financial trends that we believe may affect our financial condition, results of operations, business strategy, clinical development, short-term and long-term business
operations and objectives and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very
competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all
factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this presentation may not occur and actual results could
differ materially and adversely from those anticipated or implied in the forward-looking statements.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance,
achievements or events and circumstances reflected in the forward-looking statements will occur. We are under no duty to update any of these forward-looking statements after the
date of this presentation to conform these statements to actual results or revised expectations, except as required by law. You should, therefore, not rely on these forward-looking
statements as representing our views as of any date subsequent to the date of this presentation.
This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry.
This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any
representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections,
assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and
risk.
This presentation may not be all inclusive and may not contain all of the information that you may consider material. Neither Innovent nor any of its affiliates, shareholders,
directors, officers, employees, agents and advisors makes any expressed or implied representation or warranty as to the completeness, fairness, reasonableness of the information
contained herein, and none of them shall accept any responsibility or liability for any loss or damage, whether or not arising from any error or omission in compiling such information
or as a result of any party's reliance or use of such information. By attending or receiving this presentation you acknowledge that you will be solely responsible for your own
assessment of our business, the market and our market position and that you will conduct your own analysis and be solely responsible for forming your own view of the potential
future performance of our business.
This presentation is intended solely for investors that are qualified institutional buyers or institutional accredited investors solely for the purposes of familiarizing such investors with
Innovent and determining whether such investors might have an interest in a securities offering contemplated by Innovent . Any such offering of securities will only be made
pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933, as amended, or by means of a registration
statement (including a prospectus) filed with the SEC, after such registration statement becomes effective. No such registration statement has been filed, or become effective, as of
the date of this presentation. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in
any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Disclaimer
2Copyright© 2019 Innovent Biologics
Our Mission, Vision and Development Strategy
Company Mission
Company Vision
Company Strategy
To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people
To be the premier biopharmaceutical company in China
Robust and high quality pipeline Global standard cGMP biologics manufacturing
facility in China
3Copyright© 2019 Innovent Biologics
Our History
2011.8 Innovent was
established
2012 First IND
application to the
NMPA
2013 Strategic
alliance with
Adimab
2014 First IND
application
was approved
Manufacturing
facility was
built
2015
Strategic
partnership with
Eli Lilly
Passed audit on
GMP system
and production
facility
To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people
2016 IBI-301,IBI-303, IBI-305
entered Phase III clinical
trials
Passed GMP audits on
drug products system
2017
2018 Listed on HKEX
NDA for IBI-303, biosimilar to
adalimumab
Tyvyt granted marketing
approval by the NMPA
Strategic partnership with Incyte
Strategic alliance
with Hanmi
PD-1 monoclonal
antibody IBI-308
entered Phase III
clinical trials 2019
NDA for IBI-305,
biosimilar to
bevacizumab
IND approval for
IBI-318 bispecific
Cover Story of sintilimab
(Tyvyt ) by The Lancet
Haematology
®
®
4Copyright© 2019 Innovent Biologics
Major Accomplishments Since 2018
1 As of Mar. 11, 2019
Clinical
Advancement
Pipeline Expansion
through Partnership
Corporate
Milestone
6Entered a strategic partnership with IncyteStrategic collaboration with Incyte for pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib
(PI3Kδ inhibitor)
8Organization grows toApproximately 1200 employees1
9IPO on the Main Board of HKEXSuccessfully listed on the Main Board of HKEX (with stock code: 01801.HK) on October 31, 2018
7Continuous expansion of the manufacturing facilitiesConstruction of the 6x3000L M1b facility has been completed, and its validation is in progress
1First NDA ApprovalTyvyt (sintilimab injection) was granted marketing approval by the NMPA on Dec 24, 2018
2Three NDA Applications submitted to the NMPANDA application for sintilimab (Apr 2018), adalimumab biosimilar (Nov 2018) and bevacizumab biosimilar (Jan 2019)
3One Phase III trial completed patient enrollmentComplete patient enrollment for IBI-301 (rituximab biosimilar)
4Nine trials completed first patient doseSintilimab (6 trials); IBI-188; IBI-101; IBI-310
5Nine IND approvalsIBI-101 China & US IND; IBI-188 China & US IND; IBI-310 China IND; IBI-307 China IND; IBI-310 China IND; IBI-338
China IND; IBI-318 China IND
®
5Copyright© 2019 Innovent Biologics
As of March 11, 2019 Status (China)
IND
Candidate/
Reference Drug Target(s) Therapeutic Area: Disease Indications Commercial Rights Pre-clinical (Filed) (Accepted) Phase1 Phase 2 Phase 3 NDA Launched
sintilimab (IBI-308) PD-1
Oncology: r/r Hodgkin’s lymphoma, 1L and 2Lmelanoma, refractory gastrointestinal cancers, 2L NSCLC, 2L esophageal cancer, 1L and 2L squamous NSCLC, 1L non-squamous NSCLC, r/r NK/T-cell lymphoma, 2L ESCC, 1L gastric cancer, solid tumors, and esophageal carcinoma
Worldwide2
IBI-303 (adalimumab
biosimilar)TNF-alpha
Autoimmune: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis,ankylosing spondylitis, Crohn’sdisease, ulcerative colitis and psoriasis Worldwide2
IBI-305 (bevacizumab
biosimilar)VEGF-A Oncology: r/r NSCLC and metastatic CRC Worldwide2
IBI-301 (rituximab
biosimilar)CD20
Oncology: non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis Worldwide2
IBI-377 (Itacitinib) JAK1 Graft versus host disease (phase 3 in the US) Mainland China, HK, Taiwan
IBI-376 (Parsaclisib) PI3Kδ NHL (phase 2 in the US) Mainland China, HK, Taiwan
IBI-375 (Pemiga) tinib FGFR1/2/3 Cholanglocarcizoma, urothelial cancer (phase 2 in the US) Mainland China, HK, Taiwan
IBI-306 PCSK9Metabolic: homozygous familial hyperlipidemia; statin intolerant high CV risk
patientsMainland China, HK, Taiwan
IBI-3101 CTLA-4 Oncology: melanoma and renal cell carcinoma Worldwide
IBI-101 OX40 Oncology: advanced solid tumors, hepatitis B Worldwide
IBI-188 CD47 Oncology: B-cell lymphoma, ovarian cancer, colorectal cancer Worldwide
IBI-318PD-1/
undisclosed targetOncology: advanced tumors (undisclosed target) Mainland China, HK, Macau3
IBI-302 VEGF/Complement proteins Ophthalmology: wet AMD Worldwide
IBI-307 RANKLMetabolic: osteoporosis and lytic bone lesions associated with cancer
metastasisWorldwide
IBI-110 LAG-3 Oncology: NSCLC, melanoma, mBrCA, advanced tumors Worldwide
IBI-939 TIGIT Oncology: advanced solid tumors Worldwide
IBI-319PD-1/
undisclosed targetOncology: advanced tumors (undisclosed target) Mainland China, HK, Macau3
IBI-322 PD-L1/CD47 Oncology: PDL1/CD47 coexpressing tumors, M1 macrophage signature tumors Worldwide
IBI-315 PD-1/HER2 Oncology: Her2 + cancers, mBrCA, gastric cancer, NSCLC worldwide
IBI-323 LAG-3/PD-L1 Oncology: PDL1+ tumors with “hot tumor” phenotype Worldwide
Clinical advancement since IPO1 We are developing IBI-310 as an innovative drug candidate in accordance with NMPA regulations because ipilimumab has not been approved for marketing in China even though it has the
same amino acid sequence as ipilimumab ; 2 We and Eli Lilly will co-promote sintilimab (IBI-308) and rituximab (IBI-301) in Mainland China, Hong Kong and Macau; 3 Eli Lilly may opt in to
co-commercialize IBI-318 and IBI-319 with us in Mainland China, Hong Kong and Macau
IND approved: Dec 2016
IND approved: Sep 2017
IND approved: Jun 2018
NDA filed in Jan 2019
NDA filed in Nov 2018
NDA to be filed in Q4 2019
IND approved: Feb 2018
IND approved: Jun 2018
IND approved: Feb 2019
IND approved: Aug 2018
Biologics Small molecules
NDA approved Dec 24, 2018
Robust Pipeline across Biologics and Small Molecules
6Copyright© 2019 Innovent Biologics
Sintilimab Injection - Tyvyt® (信迪利单抗注射液– 达伯舒®)
Tyvyt (sintilimab injection) has
been granted marketing approval
by the NMPA on December 24, 2018
®
7Copyright© 2019 Innovent Biologics
Clinical Highlight of Sintilimab (Tyvyt®)
Cover Story of Sintilimab (Tyvyt®) by The Lancet Haematology
Significant unmet medical need for patients with
classical Hodgkin’s lymphoma in China
Registration trial in 96 patients with relapsed or
refractory classical Hodgkin’s lymphoma
Well tolerated with no non-PD-1 class toxicities
80.4% ORR, 34% CR
Lancet Coverage
Clinical Highlight
More than 1,000 patients were on sintilimab and its
safety profile very similar to globally approved anti-
PD-1 products
Sintilimab showed higher PD-1 occupancy in cancer
patients, suggesting potential better clinical efficacy
More than 20 trials including 7 registration studies
are under way
8Copyright© 2019 Innovent Biologics
Clinical Development Programs for Sintilimab
As of March 11, 2019Status
Indication1, 2, 3Mono-/Combo-Therapy (Other
Components)
Phase 1
Phase 2 Phase 3
NDA
Filed
NDA
Approved1a 1b
China
r/r Classical Hodgkin’s Lymphoma Mono
2L Squamous NSCLC Mono
1L Non-squamous NSCLC Combo (pemetrexed and platinum)
1L Squamous NSCLC Combo (gemcitabine and platinum)
1L Non-squamous NSCLC Combo (pemetrexed and cisplatin)
EGFR+ TKI Failure NCSLC Combo (IBI-305)
1L Hepatocellular Carcinoma Combo (IBI-305)
1L Gastric Cancer Combo (capecitabine and oxaliplatin)
1L Esophageal Carcinoma Combo (paclixel and cisplatin)
2L ESCC Mono
r/r NK/T-cell Lymphoma Mono
2L NSCLC Mono
1L/2L Melanoma Mono
Refractory Gastrointestinal Cancer Mono
2L Neuroendocrine Tumor Mono
1L Squamous NSCLC Combo (gemcitabine and cisplatin)
1L Gastric Cancer Combo (capecitabine and oxaliplatin)
Refractory Solid Tumors Mono
U.S.
Solid Tumors Mono
Late Stage Endometrial Carcinoma Mono
Notes1 Abbreviations: r/r = relapsed, refractory; 2L = second-line; 1L = first-line; NK/T-cell lymphoma = natural killer/T-cell lymphoma; ESCC = esophageal squamous cell carcinoma; NSCLC = non-small cell lung
cancer; EGFR = epidermal growth factor receptor; TKI = tyrosine kinase inhibitor.2 Symbols: = completed; = in progress = to be initiated within next quarter.3 Some indications may not require every clinical trial indicated on his chart to completed prior to the filing of an NDA.
Advancement since IPO
9Copyright© 2019 Innovent Biologics
Commercialization of Sintilimab (Tyvyt®)
Right Team and Strategy
1 As of Mar. 11, 2019
Experienced Team Strategy
Led by former vice president and head of one of
Roche’s two oncology business units in China with
expertise in the fields of lung cancer, gastrointestinal
cancers, and hematology
Key commercial leadership members have
significant commercial experience in the
pharmaceutical industry
Currently, 350-member 1 commercialization team
was built for sintilimab in China
Focus on the rapid delivery of sintilimab to
markets
Strengthen competitive share of voice in
promotion and medical services
Build extensive hands-on experience at launch
Leveraging Eli Lilly’s in-depth knowledge of
commercialization in China
Sintilimab launched sales on March 9, 2019
10Copyright© 2019 Innovent Biologics
Commercialization of Sintilimab (Tyvyt®)
Marketing Readiness
Research Fund Program Media Channel Launch Activities
To enhance HCP hands-on experiences
To fill data gap of sintilimab in different disease areas
Press conference for sintilimabcommercial launch
Engage KOLs after the approval from the NMPA (National Medical Products Administration)
11Copyright© 2019 Innovent Biologics
Pre-clinical IND Phase1 Phase 2 Phase 3 NDA Launched
Other Major Clinical Advancements
Continuous Pipeline Enhancement throughout Stage of Development
IBI-101 (OX40) Received IND Approval in Dec 2018
IBI-318 (PD-1 /
undisclosed target)Received IND Approval in Feb 2019
IBI-101 (OX40) First Patient Dosed in Feb 2019
IBI-188 (CD47) First Patient Dosed in Jan 2019
IBI-303 (Adalimumab) Filed NDA in Nov 2018
IBI-305 (Bevacizumab) Filed NDA in Jan 2019
Ch
ina
U.S
.
Filed NDA First Patient Dosed Received IND Approval
12Copyright© 2019 Innovent Biologics
State-of-the-art Manufacturing Facilities Designed to, Built to and Operating at International Standards
Innovent’s manufacturing facilities are
designed for FDA, EMA and NMPA
standards, and support the full
process from DS to DP. DS, DP and
GMP were successfully audited.
Undergone ordinary course,
comprehensive annual audits of
production facility to evaluate
compliance with industry GMP and
quality compliance standards.
Manufacturing team with extensive
experience at multi-national
pharmaceutical companies.
M1b Facility
4 x 15,000 L
Planned
3 x 1,000 L In Operation
6 x 3,000 L (cGMP
validated) Ready in 2019
Total capacity in the future: 81KL
On 29 December 2018, our manufacturing facilities received GMP certification from the NMPA for manufacturing Tyvyt® (sintilimab)
13Copyright© 2019 Innovent Biologics
Global Partners
July 2013
Therapeutic
antibody discovery
platform
June 2016
Bispecific
Antibody platform
March 2017
Bispecific
antibody collaboration
November 2018
Combination Therapy
February 2019
Combination Therapy
October 12th 2015
Innovent out licensed Ex-
China right of additional 3 PD-
1 bispecific mAbs to Lilly
In return, Innovent received
milestones >$1 billion
March 20th 2015
Innovent out licensed PD-1 mAb
Ex-China to Lilly
Co-development of 3 mAbs in
China
Upfront payment of $56 mm and
milestone payment >$0.4 bn
Dec 17th 2018
Multi-product strategic collaboration announced between Innovent and
Incyte, a well-recognized global biopharmaceutical company
Innovent strengthened its portfolio by licensing in 3 potentially best-in-
class innovative late clinical-stage product candidates for China
development and commercialization
Transformed Innovent from being a mAb development focused
company to a broader portfolio oncology focused entity
Our Other Global R&D PartnersStrategic Partnership with Renowned MNCs
14Copyright© 2019 Innovent Biologics
Pipeline Expansion through Partnership
Product Candidates Licensed from Incyte for China Market
Dec 17th 2018
Strengthened portfolio by licensing in 3 potentially Best-in-Class innovative late clinical-stage candidates, including 2
potentially First-in-Class candidates, for China development and commercialization
Transformed Innovent from being a mAb focused oncology company to a company across biologics and small
molecules
Pemigatinib
(FGFR1/2/3)
Potential First-in-Class, Best-in-Class
in treating oncology patients with
FGFR mutations
Solid tumors for Cholangiocarcinoma
(bile-duct cancer), and Urothelial
Cancer (bladder cancer)
Itacitinib
(JAK1)
Potential First-in-Class, Best-in-Class
in the treatment of GvHDGraft versus Host Disease (GvHD)
Parsaclisib
(PI3Kδ)
Potential Best-in-Class
in treating hematological malignancies Non-Hodgkin’s Lymphoma
15Copyright© 2019 Innovent Biologics
Strong Support from Globally Renowned Investors
Ten Cornerstone Investors with an Aggregate Amount of US$245 mm
US$20 mm
~US$20 mm US$25 mm
US$5 mmUS$20 mm
US$15 mmUS$60 mm
US$30 mm US$20 mm
US$30 mm
16Copyright© 2019 Innovent Biologics
Corporate Milestones
1 Up to Mar. 14, 2019
2 International Financing Review
Listed on HKEX with stock code: 01801.HK,
raising HK$3.3 billion (US$485 mm) on Oct.
31, 2018
Largest pre-revenue IPO at the time
Stock price increased over 100% since IPO¹
Superior pricing outcome with significant
over-subscription
Awarded by IFR2 as
“Asia-Pacific IPO of
the Year”
Asia-Pacific
IPO of the Year
Awarded by IFR2
Asia as
“Hong Kong
Equity Issue of the
Year”Hong Kong Equity
Issue of the Year
17Copyright© 2019 Innovent Biologics
Management with a Proven Track Record of Success
Visionary Founder, CEO and Chairman Supported by Experienced Management Team
Dr. Michael Yu
Founder, CEO & Chairman
Ph.D. in Genetics, Chinese Academy of Sciences
Inventor of Oncorine, Co-inventor of Conbercept and
sintilimab, three Class One novel biologics in China
Inventor of 60+ issued patents & patent applications
Published 50+ SCI scientific articles & book chapters
22 years of industry experience
— 1997 – 2001: Vice President, Calydon
— 2001 – 2005: Principal Scientist and Senior Director, Cell Genesys
— 2005: Vice President of R&D, Applied Genetics
— 2006 – 2010: Director, President, and CEO of Chengdu
Kanghong Biotech
— 2011 to date: Founding President and CEO of Innovent
Management Team
Qinwei Zhou, Ph.D.
Chief Operating Officer
Over 24 years of biotech and biopharma
experience
Former Vice President at Eli Lilly in
charge of bioanalytical science and Vice
President at ImClone
Ronnie Ede
Chief Financial Officer
Former CFO of Mindray Medical
International Ltd. Responsible for
Finance, Investor Relation, North
America Operations, and Internal Audits
Former CFO of Biosensors
International Ltd.
Kerry Blanchard, Ph.D., M.D.
Chief Scientific Officer
Senior Vice President China Drug
Development at Eli Lilly & Company
Responsible for building, training and
developing the drug development and
medical affairs organization and for
delivering Lilly’s internal and external
portfolio for China
Min Liu
Chief Commercial Officer
Former member of Roche Global
Oncology Franchise Leadership Team
Vice President of Business Unit
Oncology 2 at Roche Pharma China, in
charge of leading the marketing & sales
efforts for products in lung cancer,
gastrointestinal cancer, and hematology
Founder, CEO & Chairman
18Copyright© 2019 Innovent Biologics
Innovent: A Platform Company
Fully-integrated Platform with World-class Discovery, Development, Manufacturing and Commercialization
Capabilities
IBI-306
IBI-310
IBI-302
IBI-307
IBI-101
IBI-188
IBI-110
IBI-318
IBI-939
IBI-315
IBI-322
IBI-319
IBI-301
IBI-303
IBI-323
IBI-305
IBI-308
IBI-385
IBI-376
IBI-377
Clinical
Development
CMC (Manufacturing & Quality)
Discovery Commercialization
19Copyright© 2019 Innovent Biologics
Our Growth Strategies
Our Mission
To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people
Maximize the value of our
fully-integrated platform
through a global strategy
of organic growth and
collaboration
Continue to enhance our
fully-integrated platform
Rapidly advance our
clinical programs for
pipeline products
Enhance research and
development capabilities
and commercialize our
lead products
01 02 03 04
20Copyright© 2019 Innovent Biologics
Expect 4 products launched
Multiple biologics in late
stage development
Global R&D platform
Higher capacity GMP
manufacturing facility
Strong commercial capability
and capacity
2H 2021
Innovent at a Glance
20 drug candidates:
• Tyvyt launched
• 2 NDA filed (IBI-303 & IBI-305)
• 1 Phase III mAb (IBI-301)
Experienced
management team
Global standard GMP
manufacturing facility
Strategic partnership
with Eli Lilly & IncyteIncorporated
Mar-2019Aug-2011
®
21Copyright© 2019 Innovent Biologics
Near Term Catalysts
Next 12 months
Launch and commercialization of sintilimab
IBI-301 (Rituximab biosimilar) to file NDA to the NMPA in Q4 2019
Continuous clinical advancement of a number of drug candidates
The 6*3000L M1b facility will be ready for production
1
2
3
4
22Copyright© 2019 Innovent Biologics
Thanks
Q&A?
Start with Integrity, Succeed through Action
Thank you!
Recommended